EM2510C "Targeting BMP, Activin, and TGF Beta Signaling in Pulmonary Hypertension: Lessons from Human Genetics, Disease Models and Clinical Trials" (IM GR-101025)

Purpose and Overview

This seminar discusses the rationale for the development of several novel therapies, including the Activin Signaling Inhibitor (ASI) drug class, that target activin, GDF, BMP and TGF-beta signaling for the treatment of pulmonary arterial hypertension (PAH). These programs were informed by human genetics, signaling biology, biomarkers of disease, and experimental models. The early experience from these trials has raised questions about the potential mechanisms of therapeutic and adverse effects of these therapies.

Target Audience

UT Southwestern faculty, fellows, residents and medical students, community physicians, nurse clinicians, physician assistants and nurses.

Learning Objectives

At the conclusion of this activity, the participant should be able to:

  • Identify syndromic or genetic versus non-syndromic pulmonary arterial hypertension syndromes. 
  • Understand the rationale for correcting aberrant activin and BMP signaling in PAH as a paradigm for treating PAH.
  • Recognize potential adverse events related to the use of Activin Signaling Inhibitors such as sotatercept.
Course summary
Available credit: 
  • 1.00 AMA
Course opens: 
10/10/2025
Course expires: 
11/10/2025
Cost:
$0.00
Rating: 
0

Photo: First Last, M.D.
Paul B. Yu, M.D., Ph.D.
Associate Professor of Medicine
Division of Cardiology
Director, MGH Cardiovascular Research Center
Massachusetts General Hospital and Harvard Medical School

Available Credit

  • 1.00 AMA

Price

Cost:
$0.00
Please login or create an account to take this course.

Required Hardware/software

Activities should be run with recent versions of common browsers, including Internet Explorer, Firefox and Google Chrome